autoimmune disease treatment
Scope
Date
~
-
Bio & Pharma
Kwangdong to sell exclusively three global rare disease drugs
South Korean pharmaceutical company Kwangdong Pharmaceutical announced on Monday that it signed an agreement for securing exclusive sales and distri...
Jul 24, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Biopharm eyes Asia's No.1 spot in radioactive drug market
South Korea’s SK Biopharmaceuticals Co. is aiming to triple its enterprise value to $15 billion by 2026 with the goal of rising to the top run...
Jul 19, 2023 (Gmt+09:00)
-
Bio & Pharma
GI Innovation seeks to license allergy therapy to Japan in 2023
South Korea’s GI Innovation Inc. aims to complete licensing of its allergic diseases treatment candidate to a Japanese drug company by year's ...
Jul 17, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong's Nabota exceeds 600,000 customers in US
South Korea's Daewoong Pharmaceutical said on Thursday that its local loyalty program for Nabota (American name: Jeuveau) in the US, a botulinum tox...
Jul 13, 2023 (Gmt+09:00)
-
Bio & Pharma
HK inno.N releases new drug for GERD in Indonesia
South Korean bio-health company HK inno.N Corporation's new drug for gastroesophageal reflux disease (GERD) K-CAB has been officially launched in In...
Jul 10, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval in US for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P...
Jun 30, 2023 (Gmt+09:00)
-
Bio & Pharma
Asan Medical Center to establish digestive disease hospital in Dubai
Asan Medical Center announced plans on Thursday to establish a 65-bed gastrointestinal specialized hospital in Dubai Healthcare City in Dubai, UAE, ...
Jun 23, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Chemicals, AZ mark first commercial production of diabetes drugs
South Korea's SK Chemicals has joined forces with global pharmaceutical firm AstraZeneca to initiate commercial production of a chemical drug for di...
Jun 19, 2023 (Gmt+09:00)
-
Bio & Pharma
Daehwa Pharm applies for approval of anti-dementia patch in China
South Korea's Daehwa Pharm Co. is speeding up its advance into the Chinese market for anti-dementia medicine, applying for sales approval of its pat...
Jun 16, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Biopharm’s Cenobamate gets nod in Canada, to boost US sales
South Korea’s SK Biopharmaceuticals Co. has obtained the sales approval for its antiepileptic treatment Cenobamate in Canada, paving the way f...
Jun 15, 2023 (Gmt+09:00)
-
Korean startups
Bredis Healthcare, Tilda win June D.Day, Korea’s oldest startup pitch race
An early-stage startup by young entrepreneurs who developed a digital diagnostic tool for brain disease and an AI-powered business optimization prog...
Jun 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis gets approval to sell biosimilar in Europe
South Korea's Samsung Bioepis has received approval in Europe to sell a biosimilar of Soliris, a drug for the treatment of adult and children patien...
May 31, 2023 (Gmt+09:00)
-
Bio & Pharma
HanAll, Daewoong to develop Parkinson's treatment with US partner
South Korea's HanAll Biopharma Co. and Daewoong Pharmaceutical on Thursday said they concluded a contract with NurrOn Pharmaceuticals of the US on...
May 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets FDA approval for Humira biosimilar CT-P17
South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Adminis...
May 24, 2023 (Gmt+09:00)
-
Artificial intelligence
Neurophet strives to be first mover in fight against Alzheimer’s
Neurophet Inc., a South Korean startup developing artificial intelligence-powered medical solutions for brain diseases, is striving to make a breakt...
May 24, 2023 (Gmt+09:00)
-
Economy
S.Korea’s chronic disease: Decline in youth employment
The number of young workers in South Korea fell for a sixth straight month in April to its lowest point in more than two years, deepening concerns t...
May 10, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for Phase 3 clinical trials in Europe for biosimilar
South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ...
May 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong to transfer techs for autoimmune disease to US pharma
South Korea's Daewoong Pharmaceutical announced on Friday that it has signed a technology export contract for the clinical development and commercia...
Apr 28, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's Kainos Medicine exports AIDS treatment technology to China
South Korean new drug developer Kainos Medicine Inc. announced on Friday that it had signed a technology transfer agreement with Chinese pharmaceuti...
Apr 21, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare enters top 10 in hospital prescriptions in Turkey
South Korean biopharmaceutical company Celltrion Healthcare Co. on Thursday said it ranked in the top 10 out of 400 companies last year on the Turki...
Apr 21, 2023 (Gmt+09:00)
-
Korean startups
Asleep dreams big to help sleepless people worldwide find right treatment
Armed with artificial intelligence and big data technologies, Asleep hopes to find the best treatment for sleep-deprived people around the world wit...
Apr 21, 2023 (Gmt+09:00)
-
Bio & Pharma
AbClon shows promising results in clinical tests of leukemia treatment
South Korean companies are standing out in the global competition to develop chimeric antigen receptor T-cell (CAR-T) treatments, dubbed "dream" a...
Apr 19, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma, UK firm to jointly develop autoimmune disease drug
South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday that it has signed a cooperation agreement with Sygnature Discovery, a British ne...
Apr 18, 2023 (Gmt+09:00)
-
Bio & Pharma
HLB starts Phase 3 clinical trials for ophthalmic disease treatment in US
South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has started patient administration of "RGN-259," a treatment...
Apr 13, 2023 (Gmt+09:00)
-
Bio & Pharma
JW Pharma receives 1st overseas patent for its hair loss treatment
JW Pharmaceutical, a drug company based in South Korea, has received its first patent for a hair loss treatment that is currently in development. Th...
Mar 27, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's microneedle maker Raphas to enter US market
South Korea's microneedle maker Raphas Co. is expediting its entry into the American pharmaceutical market after entering the country's cosmetics se...
Mar 27, 2023 (Gmt+09:00)
-
Bio & Pharma
PharmaResearch pays employees $7,706 bonus for having 3rd child
With South Korea setting new lows in birth rate every year, PharmaResearch on Wednesday said it will adopt an unprecedented system of childbirth and...
Mar 23, 2023 (Gmt+09:00)
-
Waste management
Toray Advanced Materials acquires S.Korea's water treatment company
Toray Advanced Materials Korea Inc. announced on Monday the acquisition of Hanmee Entec Co., Ltd., the industry's longest-running water treatment fa...
Mar 20, 2023 (Gmt+09:00)
-
Bio & Pharma
Prestige Bio's pancreatic cancer treatment gets US FDA fast-track designation
Prestige Biopharma, a biopharmaceutical company in South Korea, announced on Thursday that their pancreatic cancer antibody drug, PBP1510 (Ulenistam...
Mar 16, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong wins approval for GERD treatment Fexuclu in Chile
South Korean pharmaceutical company Daewoong Pharmaceutical announced on Tuesday that it has received marketing authorization from Chile's National ...
Mar 14, 2023 (Gmt+09:00)
Latest News
- 1 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 2 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 3 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 4 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google
- 5 Kookmin Bank raises $700 mn in forex bonds amid strong demand